Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

957

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Neoplasms
Esophagogastric Junction

Interventions

DRUG: Durvalumab
DRUG: FLOT chemotherapy

Sponsor

AstraZeneca